CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02350764
NCT02350764Phase 2Completed
CompareCT.gov

An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 30, 2015·Updated May 29, 2024

In Brief

A Phase 2 clinical trial evaluating nivolumab and pilimumab for Advanced Stage Non-small Cell Lung Cancer. Completed, enrolled 29 participants across 1 site.

Detailed Summary

The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Stage Non-small Cell Lung Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 30, 2015
Enrollment StartJan 20, 2015
Primary CompletionSep 25, 2023
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 11.4 years ago

Interventions

nivolumabdrug

pilimumabdrug